AC Immune SA

NasdaqGM:ACIU Stock Report

Market Cap: US$265.2m

AC Immune Management

Management criteria checks 2/4

AC Immune's CEO is Andrea Pfeifer, appointed in Apr 2003, has a tenure of 21.67 years. total yearly compensation is CHF2.65M, comprised of 21.8% salary and 78.2% bonuses, including company stock and options. directly owns 2.45% of the company’s shares, worth $6.49M. The average tenure of the management team and the board of directors is 5.8 years and 6.7 years respectively.

Key information

Andrea Pfeifer

Chief executive officer

CHF 2.7m

Total compensation

CEO salary percentage21.8%
CEO tenure21.7yrs
CEO ownership2.4%
Management average tenure5.8yrs
Board average tenure6.7yrs

Recent management updates

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

CEO Compensation Analysis

How has Andrea Pfeifer's remuneration changed compared to AC Immune's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CHF 40m

Jun 30 2024n/an/a

-CHF 61m

Mar 31 2024n/an/a

-CHF 55m

Dec 31 2023CHF 3mCHF 578k

-CHF 54m

Sep 30 2023n/an/a

-CHF 68m

Jun 30 2023n/an/a

-CHF 67m

Mar 31 2023n/an/a

-CHF 69m

Dec 31 2022CHF 2mCHF 558k

-CHF 71m

Sep 30 2022n/an/a

-CHF 73m

Jun 30 2022n/an/a

-CHF 76m

Mar 31 2022n/an/a

-CHF 75m

Dec 31 2021CHF 2mCHF 530k

-CHF 73m

Sep 30 2021n/an/a

-CHF 71m

Jun 30 2021n/an/a

-CHF 74m

Mar 31 2021n/an/a

-CHF 71m

Dec 31 2020CHF 2mCHF 520k

-CHF 62m

Sep 30 2020n/an/a

-CHF 62m

Jun 30 2020n/an/a

-CHF 25m

Mar 31 2020n/an/a

-CHF 26m

Dec 31 2019CHF 2mCHF 510k

CHF 45m

Sep 30 2019n/an/a

CHF 50m

Jun 30 2019n/an/a

CHF 18m

Mar 31 2019n/an/a

CHF 24m

Dec 31 2018CHF 2mCHF 455k

-CHF 51m

Sep 30 2018n/an/a

-CHF 32m

Jun 30 2018n/an/a

-CHF 27m

Mar 31 2018n/an/a

-CHF 29m

Dec 31 2017CHF 2mCHF 404k

-CHF 26m

Compensation vs Market: Andrea's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Andrea's compensation has increased whilst the company is unprofitable.

CEO

Andrea Pfeifer (67 yo)

21.7yrs

Tenure

CHF 2,650,000

Compensation

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Leadership Team

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder21.7yrsCHF 2.65m2.45%
$ 6.5m
Christopher Roberts
CFO & VP of Finance2.7yrsno data0.013%
$ 33.8k
Piergiorgio Donati
Chief Technical Operations Officer5.8yrsno data0.025%
$ 65.7k
Jean-Fabien Monin
Chief Administrative Officer9.4yrsno data0.32%
$ 836.0k
Howard Donovan
Chief HR Officer2.7yrsno data0.020%
$ 54.0k
Madiha Derouazi
Chief Scientific Officerless than a yearno data0.0032%
$ 8.5k
Gary Waanders
Senior VP of Investor Relations & Corporate Communicationsno datano datano data
Alexandre Caratsch
General Counselno datano datano data
Julian Snow
VP of U.S. Finance & Corporate Development2.7yrsno datano data
David Hickman
Head of AD - SME14.9yrsno datano data
Joseph Wettstein
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer8.8yrsno datano data
Oliver Sol
VP & Head of Clinical Developmentno datano datano data

5.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: ACIU's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder8.6yrsCHF 2.65m2.45%
$ 6.5m
Jean-Marie Lehn
Chairman of Scientific Advisory Boardno datano datano data
Claude Nicolau
Member of Scientific Advisory Boardno datano datano data
Douglas Williams
Independent Non-Executive Chairman6.7yrsCHF 179.00k0.039%
$ 104.3k
Alf E. Lindberg
Member of Scientific Advisory Boardno datano datano data
Detlev Riesner
Member of Scientific Advisory Boardno dataCHF 5.00kno data
Fred Van Leuven
Member of Scientific Advisory Boardno dataCHF 105.00kno data
I. Rosenberg
Member of Scientific Advisory Boardno datano datano data
M. Monsigny
Member of Scientific Advisory Boardno datano datano data
E. Lestringant
Member of Scientific Advisory Boardno datano datano data
Monika Butler
Independent Vice Chair3.2yrsCHF 163.00k0.0092%
$ 24.5k
Andreas Monsch
Head of Clinical Advisory Boardno datano datano data

6.7yrs

Average Tenure

74.5yo

Average Age

Experienced Board: ACIU's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:44
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AC Immune SA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Alethia YoungCredit Suisse
Andrew FeinH.C. Wainwright & Co.